Citation Impact
Citing Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
2010
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
2014
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2008 Standout
Leishmaniasis
2018 Standout
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Acute kidney injury
2012 Standout
The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate
2004
Hepatocellular carcinoma
2018 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Methodology of Clinical Trials Aimed at Assessing Interventions for Cutaneous Leishmaniasis
2013
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
2014 Standout
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
2009
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Lung Cancer
2008 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Relapsed childhood acute lymphoblastic leukaemia
2013
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care*
2009
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
2006
The golden age: gold nanoparticles for biomedicine
2011 Standout
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
2008
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Heparin-Induced Thrombocytopenia
2006 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Reporting of Noninferiority and Equivalence Randomized Trials
2006
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
2015 Standout
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
2004
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
2010 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Herb-Drug Interactions
2005 Standout
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
2003
Special Invited Papers Section: Therapeutic Equivalence – Clinical Issues and Statistical Methodology in Noninferiority Trials
2005
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
2008
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
2008
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances
2009
Hepatocellular Carcinoma
2019 Standout
Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
2005
Multiple treatment comparison meta-analyses: a step forward into complexity
2011
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells
2010
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
2010
Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
2007
Addressing Missing Data in Clinical Trials
2011
Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
2006
Targeted Cancer Therapeutics
2009
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
2014
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
2013 Standout
Works of Mark D. Rothmann being referenced
Design and analysis of non‐inferiority mortality trials in oncology
2002
Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents in Patients with Cancer
2008
U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia
2011
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
2003
U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
2010
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
2002
U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
2008
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
2002
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
2012
Some essential considerations in the design and conduct of non-inferiority trials
2011
Issues in Using Progression-Free Survival When Evaluating Oncology Products
2009